Similarly, HR−/HER2-low and triple-negative breast cancers also showed comparable features with 48% being stage 1, 43–44% stage 2, 77–78% grade 3 tumours, and 48–49% measuring 21–50 mm in size, although nodal status was more variable (Table 12). Here, ERBB2 is linked to triple-negative breast carcinoma.